RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation.
about
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancerThe Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic targetTranscriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Phosphorylation of RalB is important for bladder cancer cell growth and metastasisHIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatmentLysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells.The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.Overcoming drug resistance and treating advanced prostate cancerScreening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.Mechanism of lymph node metastasis in prostate cancer.Chitin hydrolysate stimulates VEGF-C synthesis by MDA-MB-231 breast cancer cells.Associations of nm23H1, VEGF-C, and VEGF-3 receptor in human prostate cancer.Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer PatientsInvolvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
P2860
Q24310439-429FEA97-09DB-44C6-A5A4-67E907F45C3AQ30415154-FFAA5D6B-58CE-4F87-BD90-4042E53703C7Q30416201-AC2A0855-5751-4053-B8D1-2DA15B56840DQ30429890-DF98C80D-12EA-4709-92C5-D607D70DFAF5Q33642200-F2BFF364-BD3F-41C5-8FD7-301D51A14E75Q34075667-770BD2A6-946F-4A01-8985-0455A0CD1F56Q34387665-FBB43C13-B659-4665-8276-CEC6D7658550Q35083727-A53CDB3E-9A21-4809-A876-A26E02D7729CQ36328812-187DC7A8-BEC2-4F5E-86CA-86410C147020Q36685517-8FC10B8F-EA7E-4768-8DDA-B6A082474EEAQ37230780-CD5E2C76-4399-4196-8D67-E6B1D2E9CB11Q37375504-53ADA191-600C-4432-BFB7-4ED6EC56219FQ37750801-F31D3669-388C-4F37-AB17-FA1F443159F2Q38339742-9C025043-F1D6-4E16-83D2-C1691BD1CFE3Q38391611-7CB7C201-7B0B-4B56-956C-D3749A121E72Q38751690-1CDBE111-01F2-4594-8C3A-63D6B42EF4FEQ39627631-7820045F-AF38-4793-B309-EDA114BAA569Q42703522-9C70056E-2C4F-432E-AE6D-1823AE6724EFQ47340259-54BA5D75-C804-4B97-8DE0-B90DC03BB443
P2860
RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
RalA regulates vascular endoth ...... ells during androgen ablation.
@en
type
label
RalA regulates vascular endoth ...... ells during androgen ablation.
@en
prefLabel
RalA regulates vascular endoth ...... ells during androgen ablation.
@en
P2093
P2860
P356
P1433
P1476
RalA regulates vascular endoth ...... ells during androgen ablation.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209971
P407
P577
2006-09-11T00:00:00Z
P5875
P6179
1026484865